Institute of Hematology & Blood Diseases Hospital, China: Lymphoma trials

The registry lists 26 Lymphoma studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 17 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 10Phase 2 14No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic TumorsNot yet recruitingNCT07539610Phase 1
• Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingNCT07441993Phase 2
• SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic MalignanciesRecruitingNCT07153068Phase 1/2
• uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic MalignanciesRecruitingNCT07109518Phase 1
• CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesRecruitingNCT07106749Phase 1
• Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaRecruitingNCT06996132Phase 2
• Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)Not yet recruitingNCT06712173Phase 1
• Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone LymphomasRecruitingNCT06513234Phase 2
• Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLRecruitingNCT06489808Phase 2
• Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaRecruitingNCT06415708Phase 2
• MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
• GVM±R in Patients With Relapsed or Refractory Aggressive NHL.RecruitingNCT06244368Phase 2
• Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaRecruitingNCT05958719Phase 2
• Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World StudyRecruitingNCT05846763
• Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT05846750Phase 2
• Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Phase 2
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell LymphomaTerminatedNCT05318963Phase 1
• GVM±R in Patients With Relapsed or Refractory Aggressive NHLActive, not recruitingNCT05299164Phase 1
• PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's LymphomaStatus unknownNCT05137886Phase 2
• Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsStatus unknownNCT04696705Early Phase 1
• CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT04690192Phase 1/2
• γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Early Phase 1
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
• CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaCompletedNCT03029338Phase 1